Acumen Pharmaceuticals, INC

Acumen Pharmaceuticals has nominated two Enhanced Brain Delivery (EBD) development candidates for Alzheimer's disease, leveraging a collaboration with JCR Pharmaceuticals.

Acumen Pharmaceuticals, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Acumen Pharmaceuticals reported its first quarter 2026 financial results and provided a business update, highlighting progress in its Alzheimer's disease drug development programs and a cash runway into early 2027.

Acumen Pharmaceuticals reported full-year 2025 financial results and provided business updates, including anticipated late 2026 topline data for its lead Alzheimer's candidate and a mid-2027 IND filing for its Enhanced Brain Delivery program.

Acumen Pharmaceuticals raises $35.75 million in a private placement to advance its Enhanced Brain Delivery program, backed by strong preclinical data.

Acumen Pharmaceuticals provides a corporate presentation update, showcasing positive Phase 1 sabirnetug data, EBD program advancements, and a strong financial runway.

Acumen Pharmaceuticals reported a reduced net loss and increased cash reserves in Q1 2026, driven by a private placement, while advancing its Alzheimer's drug candidates.

Acumen Pharmaceuticals reported a widened net loss in Q3 2025, driven by increased R&D for its Alzheimer's drug sabirnetug, with existing capital projected to fund operations into early 2027.

Acumen Pharmaceuticals reported a significant increase in net loss for Q2 2025 driven by higher R&D expenses for its Alzheimer's drug candidate, sabirnetug, while announcing a new strategic collaboration.

Acumen Pharmaceuticals announces its Q1 2025 financial results, showcasing increased R&D spending as it advances its Alzheimer's disease drug candidate, sabirnetug, through clinical trials.

Acumen Pharmaceuticals' Q3 2024 report reveals a significant increase in research and development expenses due to the advancement of their Phase 2 ALTITUDE-AD clinical trial for sabirnetug.

Acumen Pharmaceuticals reported a net loss of $35.4 million for the first half of 2024, while advancing its Alzheimer's drug candidate, sabirnetug, into Phase 2 clinical trials.

Acumen Pharmaceuticals reported increased net losses for 2025 while advancing its lead Alzheimer's drug candidate, sabirnetug, and expanding its next-generation brain delivery platform.

Acumen Pharmaceuticals details its financial performance for 2024 and provides an update on its clinical development programs, including the Phase 2 ALTITUDE-AD trial for sabirnetug.

Acumen Pharmaceuticals secures office space in Newton, MA, while also detailing financial performance and future plans in its annual 10-K filing.

Director Derrell Porter exercised stock options and sold shares of Acumen Pharmaceuticals, Inc. (ABOS) between June 15 and June 17, 2026.

Nathan B. Fountain, a Director at Acumen Pharmaceuticals, Inc., reported a sale of 6,400 shares of common stock on June 9, 2026.

Acumen Pharmaceuticals director Laura Stoppel received a grant of restricted stock units and stock options as part of her board compensation.

Director Nathan B. Fountain received a grant of 35,500 restricted stock units and 53,250 stock options.

Director Kimberlee C. Drapkin was granted 35,500 restricted stock units and 53,250 stock options by Acumen Pharmaceuticals.

Director John A. Stalfort III was granted 35,500 restricted stock units and 53,250 stock options by Acumen Pharmaceuticals.

Acumen Pharmaceuticals announces its 2026 Annual Meeting of Stockholders to be held virtually on June 3, 2026.

Acumen Pharmaceuticals has filed a definitive proxy statement related to its upcoming shareholder meeting.

Acumen Pharmaceuticals announces its 2025 Annual Meeting of Stockholders to be held virtually on June 4, 2025, featuring proposals for director elections and ratification of the independent accounting firm.

Acumen Pharmaceuticals will hold its annual stockholders meeting on June 4, 2024, to elect directors and ratify the selection of its independent accounting firm.

Acumen Pharmaceuticals announces its 2024 Annual Meeting of Stockholders to be held virtually on June 4, 2024, featuring proposals for director elections and ratification of the independent accounting firm.

RA Capital Management, L.P. and its affiliates have filed an amendment to their Schedule 13D, reporting a 24.8% beneficial ownership in Acumen Pharmaceuticals, Inc., a change primarily driven by an increase in the issuer's outstanding shares rather than new transactions by the reporting group.

James B. Murray Jr. has reported beneficial ownership of 5.00% of Acumen Pharmaceuticals' common stock as of April 6, 2026, with a filing delay noted.

Franklin Resources, Inc. reports a reduced beneficial ownership of 3.8% in Acumen Pharmaceuticals, Inc. common stock.

Sands Capital Alternatives and affiliated funds reported a 5.6% beneficial ownership stake in Acumen Pharmaceuticals, Inc. as of June 30, 2025.